Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + CCRT in Unresectable HPV-Negative HNSCC
NCT07776340Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Fudan University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07776340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776340.